guidance.fyi
Company, ticker, metric, guidance, or anything said
VIYASH
1 call

Concalls & earnings callsViyash Scientific Limited

Every summarised call, newest first. Latest is Q1 FY27, held 12 Aug 2026.

Latest quarter

Q1 FY27 snapshot

Open full brief →

Viyash delivered strong Q1 growth with improved margins and a strengthened, nearly debt-free balance sheet, positioning it for strategic investments in R&D, manufacturing, and targeted M&A.

MetricThis quarterChangeFive-quarter trend
Revenue from Operations₹946 Cr20%
EBITDA₹205 Cr59%
EBITDA Margin21.6%530 bps
Profit After Tax₹79 Cr115%
Latest guidance
  • Sustained double-digit revenue growth and EBITDA margins around 20%-22%.
  • API business expected to see strong traction, with Q2 anticipated to be the best quarter.
  • Total ESOP cost for FY27 estimated at ~Rs 150 crores, falling to Rs 25-30 crores in FY28.
  • Full-year capex expected to be in the range of Rs 250-300 crores.
  • Long-term target of $1 billion revenue by 2032 (18% CAGR).
  • Minority interest buyback planned within the next 1-2 years.

Said on the Q1 FY27 call.

Filed results

Reported quarterly history

From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.

QuarterRevenueNet profit (PAT)Basic EPS
Q3 FY25₹390.81 Cr+18.7% YoY+6% QoQ₹6.48 Cr-39.3% YoY+2.2% QoQ₹0.14-57.6% YoY+40% QoQ
Q2 FY25₹368.65 Cr+6.6% YoY-5.5% QoQ₹6.34 CrTurned profitable YoY-30% QoQ₹0.10Turned positive YoY-61.5% QoQ
Q1 FY25₹390.21 Cr+17.1% YoY+8% QoQ₹9.06 CrTurned profitable YoY+613.4% QoQ₹0.26Turned positive YoYTurned positive QoQ
Q4 FY24₹361.20 Cr-1.5% YoY+9.7% QoQ₹1.27 CrTurned profitable YoY-88.1% QoQ₹-0.04Loss/share narrowed YoYTurned negative QoQ
Q3 FY24₹329.36 Cr-12.2% YoY-4.8% QoQ₹10.68 CrTurned profitable YoYTurned profitable QoQ₹0.33Turned positive YoYTurned positive QoQ
Call history
  • Q1 FY27Positive tone

    Viyash delivered strong Q1 growth with improved margins and a strengthened, nearly debt-free balance sheet, positioning it for strategic investments in R&D, manufacturing, and targeted M&A.

    Revenue from Operations
    ₹946 Cr20%
    EBITDA
    ₹205 Cr59%
    Pharmaceuticals & HealthcareVerified brief6 guidance items